ArticleNPJ breast cancer2026
Cancer-associated adipomes promote invadopodia formation and enhance metastatic potential in triple-negative breast cancer.
Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lysosomal lipid metabolism promotes tumor cell invasion through local energetics and membrane lipid remodeling.bioRxiv : the preprint server for biology · 2026Article
- The chemokine network in triple-negative breast cancer: its role in immune microenvironment regulation, and prospects for targeted therapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-Negative Breast Cancer (TNBC), which accounts for 15-20% of all breast cancer cases, remains one of the most aggressive and therapeutically challenging subtypes due to its lack of hormone receptors and HER2 expression, leaving chemotherapy as the primary treatment option. TNBC is characterized by early relapses and visceral metastasis, underscoring the urgent need to elucidate the mechanisms driving metastasis. The metastatic cascade begins with cancer cell invasion of the surrounding stroma, a process mediated by actin-rich protrusions called invadopodia that degrade the extracellular matrix (ECM). While the molecular machinery of invadopodia is well characterized, the upstream tumor microenvironment (TME) signals that regulate their formation remain poorly understood. In breast cancer, the TME is predominantly composed of mammary adipose tissue, where adipocytes undergo reprogramming into cancer-associated adipocytes (CAAs) that release extracellular vesicles, termed 'adipomes'. These adipomes serve as intercellular messengers, transferring bioactive molecules that can alter tumor cell behavior. Using a novel purification method, large (L)-adipomes were isolated from the plasma of TNBC subjects as well as from tumor-associated mammary fat (TAMF) using a murine TNBC model (EO771-C57BL/6) to investigate their role in invasion. Circulating L-adipomes from metastatic TNBC subjects induced epithelial-to-mesenchymal transition (EMT) and stemness signaling and promoted invadopodia formation in human non-tumorigenic breast epithelial cells, while TAMF-derived L-adipomes from metastatic-stage mice were enriched in phospholipids and promoted transcriptional and functional reprogramming in murine TNBC cells. Integrated transcriptomic and proteomic analyses revealed that adipomes activate stress-responsive MAPK signaling and upregulate proteins involved in actin cytoskeletal remodeling, mitochondrial metabolism, and translational machinery, pathways known to support invadopodia formation and extracellular matrix (ECM) degradation. Together, these findings establish adipocyte-derived adipomes as potent regulators of TNBC invasion and metastasis and reveal a previously unrecognized tumor-adipocyte signaling axis that may present new opportunities for therapeutic targeting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.